Home >> Industry News >> FDA clears Promega OncoMate MSI Dx system

FDA clears Promega OncoMate MSI Dx system

image_pdfCreate PDF

OncoMate MSI is a fluorescent, multiplex PCR-based fragment-sizing test. The system targets five mononucleotide repeat markers (BAT-25, BAT-26, NR-21, NR-24, and MONO-27) that were selected for high sensitivity and specificity to alterations in repeat lengths in samples containing mismatch repair defects. Turnaround time is as few as 10 hours.

CAP TODAY
X